Read More

WTW Enters Co-Brokerage Agreement With The Solomon Agency Corp To Align Resources To Deliver Brokerage Support And Customized Insurance Solutions To North American Exposures Of Companies With Headquarters In South Korea And Vietnam

WTW (NASDAQ:WTW), a leading global advisory, broking, and solutions company, today announced a co-brokerage arrangement with the Solomon Agency Corporation. Focusing on insurance brokerage, risk management and related

WTW

Read More

Scilex Announces Filing Of A New Drug Submission To Health Canada’s Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For The Approval Of ELYXYB For Acute Treatment Of Migraine With Or Without Aura In Canada

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is

SCLX

Read More

Amgen Provides Regulatory Update On Status Of Lumakras; FDA Has Issued New Postmarketing Requirement; LUMAKRAS Dosing Confirmed At 960 mg Once-Daily For Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif., Dec. 26,

AMGN